Author: Pan, Feng; Yang, Lian; Liang, Bo; Ye, Tianhe; Li, Lingli; Li, Lin; Liu, Dehan; Wang, Jiazheng; Hesketh, Richard L.; Zheng, Chuansheng
Title: Chest CT Patterns from Diagnosis to 1 Year of Follow-up in COVID-19 Cord-id: pho0sbky Document date: 2021_10_5
ID: pho0sbky
Snippet: BACKGROUND: The chest CT manifestations of COVID-19 from hospitalization to convalescence after one year are not known. PURPOSE: To assess chest CT manifestations of COVID-19 up to 1 year after symptom onset. MATERIALS AND METHODS: Patients were enrolled if they were admitted to the hospital due to COVID-19 and underwent CT scans during hospitalization at two isolation centers between 27 January and 31 March 2020. In a prospective study, three serial chest CTs were obtained at approximately 3, 7
Document: BACKGROUND: The chest CT manifestations of COVID-19 from hospitalization to convalescence after one year are not known. PURPOSE: To assess chest CT manifestations of COVID-19 up to 1 year after symptom onset. MATERIALS AND METHODS: Patients were enrolled if they were admitted to the hospital due to COVID-19 and underwent CT scans during hospitalization at two isolation centers between 27 January and 31 March 2020. In a prospective study, three serial chest CTs were obtained at approximately 3, 7, and 12 months after symptom onset and longitudinally analyzed. The total CT score of pulmonary lobe involvement from 0 to 25 was assessed (score 1-5 for each lobe). Uni-/multi-variable logistic regression tests were performed to explore independent risk factors for residual CT abnormalities after one year. RESULTS: 209 study participants (mean age: 49±13 years, 116 women) were evaluated. At 3 months, 61% of participants (128 of 209) had resolution of CT abnormalities; at 12 months, 75% (156 of 209) had resolution. Of chest CT abnormalities that had not resolved, there were residual linear opacities in 25/209 (12%) and multifocal reticular/cystic lesions in 28/209 (13%) participants. Age≥50 years, lymphopenia, and severe/ARDS aggravation were independent risk factors for residual CT abnormalities at one year (odds ratios of 15.9, 18.9, and 43.9, respectively; P<.001, each). In 53 participants with residual CT abnormalities at 12 months, reticular lesions (41 of 53, 77%) and bronchial dilation (39 of 53, 74%) were observed at discharge and were persistent in 53% (28 of 53) and 45% (24 of 53) of participants, respectively. CONCLUSION: One year after COVID-19 diagnosis, chest CT showed abnormal findings in 25% of participants, with 13% showing subpleural reticular/cystic lesions. Older participants with severe COVID-19 or acute respiratory distress syndrome were more likely to develop lung sequelae that persisted at 1 year. See also the editorial by Lee and Wi.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and admission ct score: 1
- acute ards respiratory distress syndrome and admission decrease: 1
- acute ards respiratory distress syndrome and admission increase: 1
- acute ards respiratory distress syndrome and admission symptom onset: 1, 2, 3, 4
- acute ards respiratory distress syndrome and logistic regression test: 1, 2
- acute ards respiratory distress syndrome and long follow: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and long term impact: 1, 2, 3, 4
- acute ards respiratory distress syndrome and longitudinal analysis: 1, 2
- acute ards respiratory distress syndrome and lung abnormality: 1, 2
- acute ards respiratory distress syndrome and lung change: 1, 2, 3
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung fibrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- acute ards respiratory distress syndrome and lung fibrosis develop: 1, 2
- acute ards respiratory distress syndrome and lung fibrosis infection sequelae: 1
- acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung lesion: 1
- acute ards respiratory distress syndrome and lung sequelae: 1, 2, 3
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- acute respiratory syndrome and additional lung infection: 1
Co phrase search for related documents, hyperlinks ordered by date